Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing-Reference-Cited by-同舟云学术

Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing

Published:2015-09 Issue:9 Volume:21 Page:1565-1575
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Yeung Cecilia C.S.,Gerds Aaron T.^ORCID,Fang Min,Scott Bart L.,Flowers Mary E.D.,Gooley Ted,Deeg H. Joachim

Funder

National Cancer Institute

National Institutes of Health

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference41 articles.

1. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS;Deeg;Blood,2012

2. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors;Mielcarek;Biol Blood Marrow Transplant,2007

3. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia;Lim;J Clin Oncol,2010

4. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge;Schanz;J Clin Oncol,2012

5. Revised international prognostic scoring system for myelodysplastic syndromes;Greenberg;Blood,2012

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation;Journal of Clinical Oncology;2024-04-20

2. Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation;Blood Journal;2023-12-14

3. A Novel Constitutional t(3;8)(p26;q21) and ANKRD26 and SRP72 Variants in a Child with Myelodysplastic Neoplasm: Clinical Implications;Journal of Clinical Medicine;2023-04-28

4. Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study;Cancer;2023-03-23

5. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines;Transplantation and Cellular Therapy;2023-02